Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Tundra lists 1 Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07583810

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib in combination with rituximab may be safe, tolerable and/or effective in treating patients with marginal zone lymphoma.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-13

1 state

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma